| Literature DB >> 24499460 |
Harald Rief1, Georg Omlor, Michael Akbar, Thomas Welzel, Thomas Bruckner, Stefan Rieken, Matthias F Haefner, Ingmar Schlampp, Alexandros Gioules, Daniel Habermehl, Friedbert von Nettelbladt, Jürgen Debus.
Abstract
BACKGROUND: Spinal bone metastases are commonly diagnosed in cancer patients. The consequences are pain both at rest and under exercise, impairment of activities of daily life (ADL), reduced clinical performance, the risk of pathological fractures, and neurological deficits. The aim of this randomized, controlled pilot trial was to investigate the feasibility of muscle-training exercises in patients with spinal bone metastases under radiotherapy. Secondary endpoints were local control, pain response and survival.Entities:
Mesh:
Year: 2014 PMID: 24499460 PMCID: PMC3923729 DOI: 10.1186/1471-2407-14-67
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Flow of participants through the trial.
Figure 2Taneichi score [20].
Patient characteristics at baseline
| Age (years) | |||||
| Mean (SD) | 61.3 (10.1) | | 64.1 (10.9) | | 0.304 |
| Gender | |||||
| Male | 14 | 46.7 | 19 | 63.3 | 0.195 |
| Female | 16 | 53.3 | 11 | 36.7 | |
| Weight (kg, SD) | 74.3 (14.7) | | 72.7 (12.1) | | 0.553 |
| Height (cm, SD) | 171.2 (8.3) | | 172.3 (7.5) | | 0.906 |
| Body mass index | |||||
| Mean (SD) | 25.3 (4.5) | | 24.4 (3.6) | | 0.559 |
| Karnofsky-index (median, range) | 80 (70–100) | | 80 (70–100) | | 1.000 |
| Primary site | |||||
| Lung cancer | 12 | 9.2 | 8 | 26.6 | 0.320 |
| Breast cancer | 5 | 16.7 | 6 | 20.1 | 0.542 |
| Prostate cancer | 5 | 16.7 | 9 | 30.1 | 0.156 |
| Melanoma | 1 | 3.3 | 1 | 3.3 | 1.000 |
| Renal cancer | 1 | 3.3 | 2 | 6.7 | 0.875 |
| Other | 6 | 20.1 | 4 | 13.4 | 0.325 |
| Localization metastases | | | | | 0.717 |
| Thoracic | 17 | 56.7 | 14 | 46.7 | |
| Lumbar | 9 | 30.0 | 13 | 43.3 | |
| Thoracic and lumbar | 2 | 6.7 | 2 | 6.7 | |
| Sacrum | 2 | 6.7 | 1 | 3.3 | |
| Number metastases | | | | | 0.257 |
| Mean (range) | 1.4 (2–4) | | 1.7 (1–5) | | |
| Solitary | 22 | 73.3 | 18 | 60.0 | |
| Multiple | 8 | 26.7 | 12 | 40.0 | |
| Type of metastases | | | | | 0.961 |
| Mixed | 2 | 6.7 | 2 | 6.7 | 1.000 |
| Osteoblast | 9 | 30.0 | 10 | 33.3 | 0.956 |
| Osteolytic | 19 | 63.3 | 18 | 60.0 | .0932 |
| Distant metastases at baseline | | | | | |
| Visceral | 12 | 40.0 | 5 | 16.7 | 0.045 |
| Brain | 3 | 10.0 | 3 | 10.0 | 1.000 |
| Lung | 7 | 23.3 | 4 | 13.3 | 0.320 |
| Tissue | 8 | 26.7 | 6 | 20.0 | 0.542 |
| Hormonotherapy | 10 | 33.3 | 16 | 53.3 | 0.118 |
| Immunotherapy | 7 | 23.3 | 5 | 16.7 | 0.519 |
| Chemotherapy | 25 | 83.3 | 20 | 66.7 | 0.136 |
| Pathological fracture at baseline | 6 | 20.0 | 9 | 30.0 | 0.379 |
| Neurological deficit | 0 | 0.0 | 2 | 6.7 | 0.150 |
| Orthopedic corset at baseline | 7 | 23.3 | 5 | 16.7 | 0.519 |
| Radiotherapy dose completed (Gy) | | | | | 0.136 |
| Single dose (median, range) | 3 (2–4) | | 3 (2–4) | | 1.000 |
| Cumulative dose (median, range) | 30 (30–40) | 30 (30–40) | 1.000 | ||
Abbreviations: SD Standard deviation.
Questions of the activity questionnaire
| 1. | I don’t have any trouble putting on my socks/shoes on my own. (absolutely true = 1 to absolutely false = 6) |
| 2. | I don’t have any trouble putting on a t-shirt on my own. (absolutely true = 1 to absolutely false = 6) |
| 3. | I have trouble getting up from a low chair. (absolutely true = 1 to absolutely false = 6) |
| 4. | I don’t have any trouble getting into a car. (absolutely true = 1 to absolutely false = 6) |
| 5. | The longest distance I can currently walk is approx. <100 m; 100–500 m; 500-1000 m; 1–2 km; 2–5 km; > 5 km |
| 6. | After covering this distance I’m thoroughly exhausted. (absolutely true = 1 to absolutely false = 6) |
| 7. | I’m still capable of riding a bicycle yes = 1; no = 0 |
| 8. | The longest riding distance I’m still capable of is approx. <2 km; 2–5 km; 5–10 km; 10–15 km; 15–20 km; >20 km |
| 9. | After riding this distance I’m thoroughly exhausted. (absolutely true = 1 to absolutely false = 6) |
| 10. | I can walk up stairs from one storey to the next with ease. (absolutely true = 1 to absolutely false = 6) |
| 11. | I don’t have any trouble carrying a shopping basket approx. 50 m. (absolutely true = 1 to absolutely false = 6) |
Intervention group
| | | | | | |
| Felling sluggish (pts. 1–6) | 2.8 | 0.9 | 1.2 | 2.9 | 5.4 |
| Psychological stress (pts. 1–6) | 2.6 | 0.9 | 1.2 | 2.8 | 5.1 |
| | | | | | |
| Felling sluggish (pts. 1–6) | 2.2 | 0.9 | 1.1 | 2.0 | 5.0 |
| Psychological stress (pts. 1–6) | 2.1 | 0.8 | 1.1 | 1.9 | 4.6 |
| Teatment effect (previous vs. after) | p < .001 in both parameters | | |||
| Difference T0-T2 | p < .001 in both parameters | | |||
| Pain during intervention (n, %) | | 5 (16.7) | | | |
| Pain medication needed (n, %) | 4 (13.3) | ||||
This table shows the results of a questionnaire previous and after intervention respective feeling sluggish and psychological stress (pt 1 = least to pt 6 = most). Treatment effect (previous vs. after training) and difference in both parameters were significant (p < .001). Pain during intervention was documented according VAS-scale (0–10). Concomitant pain medication during intervention was evaluated (number of patients, %).
Results of “chair stand test” and pain response
| | | | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (t0) | 30 | 5.1 | 1.4 | 2.0 | 5.0 | 7.0 | 30 | 4.6 | 2.0 | 0.0 | 4.0 | 9.0 |
| End of RT (t1) | 30 | 6.7 | 1.9 | 4.0 | 6.5 | 12.0 | 30 | 4.9 | 2.2 | 0.0 | 5.0 | 10.0 |
| After 3 month (t2) | 25 | 9.0 | 2.6 | 5.0 | 10.0 | 13.0 | 23 | 5.0 | 2.7 | 0.0 | 5.0 | 10.0 |
| Treatment effect within groups (t2) | | p < .001 | | | | | | p = 0.525 | | | | |
| Treatment effect between groups (t2) | | p < .001 | | | | | | | | | | |
| | | | | | | | | | | | | |
| Pain score at baseline (VAS) | 30 | 4.8 | 2.1 | 0.5 | 5.0 | 9.0 | 30 | 5.1 | 2.7 | 0.0 | 5.3 | 9.0 |
| Pain score end of RT (VAS) | 30 | 2.4 | 2.0 | 0.0 | 2.0 | 8.0 | 30 | 3.3 | 2.5 | 0.0 | 3.3 | 9.0 |
| Pain score after 3 month (VAS) | 25 | 1.9 | 1.4 | 0.0 | 1.5 | 5.0 | 23 | 3.8 | 2.3 | 0.0 | 4.5 | 7.0 |
| Treatment effect within groups (t2) | | p < .001 | | | | | | p = 0.010 | | | | |
| Treatment effect between groups (t2) | | p = 0.003 | | | | | | | | | | |
| No response (n, %) | 8 | 32% | | | | | 12 | 52.2% | | | | |
| Partial response (n, %) | 5 | 20% | | | | | 6 | 26.1% | | | | |
| Complete response (n, %) | 12 | 48% | | | | | 5 | 21.7% | | | | |
| Treatment effect (t2) | p = 0.158 | |||||||||||
The “chair stand test” showed an improvement in intervention group over the course (p < .001), and between groups in favor to intervention group (p < .001). The intervention group improved in pain score (VAS, 0–10) over the course (p < .001), and was significant better between groups (p = .003) after 3 month. The overall pain response showed no significant difference between groups (p = .158). Wilcoxon U test was used between groups, signed-rank test was used within groups. Chi-square test was measured for pain response.
Results of activity questionnaire of both groups
| | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | ||||||||||||
| 1 | 2.5 | 1.0 | 6.0 | 1.8 | 1.0 | 5.0 | 0.063 | 3.6 | 1.0 | 6.0 | 3.2 | 1.0 | 6.0 | 0.022 |
| 2 | 2.6 | 1.0 | 6.0 | 2.0 | 1.0 | 6.0 | 0.137 | 3.4 | 1.0 | 6.0 | 3.6 | 1.0 | 6.0 | 0.028 |
| 3 | 3.5 | 1.0 | 6.0 | 3.6 | 1.0 | 6.0 | 0.490 | 3.8 | 1.0 | 6.0 | 3.1 | 1.0 | 6.0 | 0.255 |
| 4 | 2.3 | 1.0 | 6.0 | 1.9 | 1.0 | 6.0 | 0.011 | 3.6 | 1.0 | 6.0 | 3.1 | 1.0 | 6.0 | 0.063 |
| 5 | 2326.7 | 100 | 5000 | 2768.0 | 100 | 5000 | 0.061 | 1430.0 | 100 | 5000 | 1882.6 | 100 | 5000 | 0.109 |
| 6 | 3.0 | 1.0 | 6.0 | 2.8 | 1.0 | 6.0 | 1.000 | 2.9 | 1.0 | 6.0 | 2.6 | 1.0 | 6.0 | 0.791 |
| 7 | 0.4 | 0.0 | 1.0 | 0.5 | 0.0 | 1.0 | 0.426 | 0.3 | 0.0 | 1.0 | 0.4 | 0.0 | 1.0 | 0.548 |
| 8 | 2466.7 | 0.0 | 10000 | 4400.0 | 0.0 | 15000 | 0.708 | 3000.0 | 0.0 | 20000 | 3347.8 | 0.0 | 20000 | 0.478 |
| 9 | 1.3 | 0.0 | 6.0 | 1.6 | 0.0 | 6.0 | 0.848 | 1.6 | 0.0 | 6.0 | 1.8 | 0.0 | 6.0 | 0.945 |
| 10 | 2.8 | 1.0 | 6.0 | 2.6 | 1.0 | 6.0 | 0.008 | 4.1 | 1.0 | 6.0 | 3.7 | 1.0 | 6.0 | 0.080 |
| 11 | 3.8 | 1.0 | 6.0 | 3.3 | 1.0 | 6.0 | 0.675 | 4.0 | 1.0 | 6.0 | 3.3 | 1.0 | 6.0 | 0.974 |
Figure 3Overall survival of both arms, time in month.